Почетна › Сквамозноклеточен карцином на глава и врат › Пенсилванија › Pittsburgh
Клинички испитувања за Сквамозноклеточен карцином на глава и врат во Pittsburgh, PA
22 студии за Сквамозноклеточен карцином на глава и врат бараат учесници на локации во и околу Pittsburgh (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Се регрутираФаза 3
- Allegheny General Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Shadyside Hospital, Pittsburgh
- и уште 7
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Се регрутираФаза 2/3
- Site #0103, Pittsburgh
- Site #0123, Pittsburgh
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Се регрутираФаза 1
- Exelixis Clinical Site #32, Pittsburgh
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Се регрутираФаза 3
- UPMC-Saint Margaret, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- и уште 4
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Се регрутираФаза 1
- Research Site, Pittsburgh
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Се регрутираФаза 2
- UPMC Hillman Cancer Center, Pittsburgh
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Се регрутираФаза 2
- UPMC-Saint Margaret, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Се регрутираФаза 2
- UPMC-Magee Womens Hospital, Pittsburgh
- UPMC-Saint Margaret, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- и уште 9
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Се регрутираФаза 1
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Се регрутираФаза 1/2
- Research Site, Pittsburgh
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Се регрутираФаза 2/3
- UPMC-Magee Womens Hospital, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- UPMC-Shadyside Hospital, Pittsburgh
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Се регрутираФаза 2
- UPMC-Saint Margaret, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- UPMC-Shadyside Hospital, Pittsburgh
- и уште 5
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Се регрутираФаза 2
- UPMC Hillman Cancer Center, Pittsburgh
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Се регрутираФаза 1
- UPMC Hillman Cancer Ctr /ID# 225706, Pittsburgh
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Се регрутираФаза 3
- GSK Investigational Site, Pittsburgh
Window of Opportunity in Preserving Laryngeal Function Trial
Се регрутираФаза 2
- UPMC Hillman Cancer, Pittsburgh
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Се регрутираФаза 3
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
A Study of VET3-TGI in Patients With Solid Tumors
Се регрутираФаза 1
- UPMC- Hillman Cancer Center, Pittsburgh
Use of SPY Imaging System to Minimize Fistulas After Hypopharyngeal Reconstruction
Се регрутираФаза 2
- UPMC, Pittsburgh
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Се регрутираФаза 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Се регрутираФаза 1
- UPMC Hillman Cancer Center, Pittsburgh
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Се регрутираФаза 1/2
- University of Pittsburgh, Pittsburgh
Испитувања за Сквамозноклеточен карцином на глава и врат во други градови
- Houston, TX47 студии
- Los Angeles, CA42 студии
- Boston, MA40 студии
- New York City, NY39 студии
- Nashville, TN39 студии
- St. Louis, MO28 студии
- Arlington, VA26 студии
- Philadelphia, PA26 студии
- Chicago, IL26 студии
- Atlanta, GA24 студии
- San Antonio, TX22 студии
- New Haven, CT22 студии
Други студии во Pittsburgh
- Рак на бели дробови со не-мали клетки48 студии
- Рак (сите типови)41 студија
- Рак на дојка39 студии
- Колоректален карцином32 студии
- Метастатски карцином31 студија
- Меланом31 студија
- Карцином на јајниците30 студии
- Рак на ендометриумот23 студии
- Рак на простата23 студии
- Рак на бели дробови23 студии
- Шлог22 студии
- Депресија22 студии
Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.